Research Article
Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study
Table 2
Lymph node marking with Magseed®.
| | | Overall (%) | Patients (Post-NAST) (%) | Patients (Pre-NAST) (%) |
| | Identification and retrieval of Magseed® marked nodes | | Patients (n) | 81 | 37 | 44 | | No | 0 (0) | 0 (0) | 0 (0) | | Yes | 81 (100.0) | 37 (100.0) | 44 (100.0) | | Concordance between SLN and MLN | | No | 15 (18.5) | 5 (13.5) | 10 (22.7) | | Yes | 66 (81.5) | 32 (86.5) | 34 (77.3) | | Nodes retrieved per patient in TAD | | Mean (SD) | 1.5 (1.2) | 1.5 (1.1) | 1.5 (1.3) | | 95% CI | (1.3; 1.8) | (1.2; 1.9) | (1.2; 1.9) | | Median (min; max) | 1.0 (1.0; 8.0) | 1.0 (1.0; 6.0) | 1.0 (1.0; 8.0) | | P25; P75 | 1.0; 1.0 | 1.0; 2.0 | 1.0; 1.0 | | Total SLNs retrieved (n) | 200 | 98 | 102 | | Total MLNs retrieved (n) | 98 | 45 | 53 | | Metastasis in MLN | | No | 37 (45.7) | 20 (54.1) | 17 (38.6) | | Yes | 44 (54.3) | 17 (45.9) | 27 (61.4) | | Metastasis in SLN | | No | 42 (51.9) | 21 (56.8) | 21 (47.7) | | Yes | 39 (48.1) | 16 (43.2) | 23 (52.3) | | Metastasis in ALND (in non-SLNs or non-MLNs) | | Patients (n) | 75 | 31 | 44 | | No | 54 (72) | 24 (77.4) | 30 (68.2) | | Yes | 21 (28) | 7 (22.6) | 14 (31.8) | | Nodes retrieved per patient in ALND | | Mean (SD) | 10.1 (4.6) | 9.9 (5.0) | 10.3 (4.3) | | 95% CI | (9.0; 11.3) | (8.0; 11.8) | (8.9; 11.7) | | Median (min; max) | 10.0 (1.0; 26.0) | 10.0 (1.0; 26.0) | 10.0 (2.0; 24.0) | | P25; P75 | 8.0; 12.0 | 6.5; 12.0 | 8.0; 11.0 | | Total nodes retrieved in ALND (n) | 638 | 268 | 370 |
|
|
ALND, axillary lymph node dissection; MLN, marked lymph node; NAST, neoadjuvant systemic therapy; SLN, sentinel lymph node; SLNB, sentinel lymph node biopsy; TAD, targeted axillary dissection.
|
